The present invention provides methods for treating patients diagnosed with colorectal cancer and metastatic colorectal cancers in a chemotherapeutic regimen comprising the administration of [6R]-5,10-methylene tetrahydrofolate (6R-MTHF), 5-fluorouracil (5-FU), bevacizumab, and oxaliplatin. The methods reduce disease progression and provide improved overall response rates compared to standard treatments with other folates such as folinic acid.

A method for identifying a subject having at least an indication or predisposition for developing inflammatory bowel disease or colorectal cancer based upon the presence of Salmonella AvrA protein, nucleic acids and antibodies is provided as is a method for treating Salmonella infection-related colorectal cancer using a Wnt1 agonist.

Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.

This disclosure provides kits and methods for detecting markers in a sample from a subject with unknown status and generating a risk assessment of the presence or absence of cancer, such as colorectal cancer. In embodiments, a kit comprises at least two reagents, each specifically binding to one of at least two polypeptides in a sample from the subject. The polypeptides include IL-8 and ferritin. The kit further includes at least one standard comprising a known amount of at least one of the polypeptides. The kit can also include computer readable media comprising instructions to analyze the detected amounts of the at least two polypeptides using a machine learning algorithm to determine whether a subject has an increased risk of the presence of colorectal cancer.

Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.

A method of evaluating gastrointestinal cancer risk. The method comprises generating a set of features comprising a plurality of current blood test results from a blood collected from a target individual, providing at least one classifier generated according to an analysis of a plurality of respective historical blood test results of each of another of a plurality of sampled individuals, and evaluating, using a processor, a gastrointestinal cancer risk of the target individual by classifying the set of features using the at least one classifier.

The present invention relates to EPLIN as a biomarker for cancer and particularly small-size (T1/T2N0 and/or stage I/II) cancer. Thus, the invention provides use of EPLIN and an in vitro method of prognosing cancer or diagnosing aggressive cancer in a subject on the basis of the expression level of EPLIN. Also provided is a method for selecting treatment for cancer or predicting response to treatment. Also provided is a kit for use in said methods.

Provided herein are materials and methods for isolation of eukaryotic nucleic acid from a human or non-human animal stool sample. Also provided are methods of analysis of eukaryotic biomarkers present in a human or non-human animal stool sample.

The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

Methods and systems for predictive measures of anti-EGFR therapy response in wild type RAS/EGFR+ samples, e.g., histochemical staining methods for staining EGFR, AREG, and EREG, digital analysis of stained slides, and scoring algorithms that allow prediction of a response to anti-EGFR therapies. Analysis of the stained slides and scoring algorithms may include but are not limited to: a percent tumor cell positivity, computerized clustering algorithms, area density (e.g., area of tumor positive for one or more markers over total tumor area), average intensity (e.g., computerized methodology measuring average gray scale pixel intensity), average intensity broken down according to membrane, cytoplasmic, or punctate staining patterns), or any other appropriate parameter or combination of parameters. The methods of the present invention allow for resolving spatial expression patterns of the ligands and the receptor to determine what patterns are predictive for response to anti-EGFR therapies.